HIF-1alpha-stabilizing long noncoding RNA (HISLA)

HIF-1alpha-stabilizing long noncoding RNA (HISLA, LINC01146) is a long intergenic non-protein coding RNA, predominantly expressed in certain tissues such as liver. HISLA is functionally implicated in cancer, especially hepatocellular carcinoma, where its expression is frequently reduced and is associated with a more aggressive disease phenotype and poorer prognosis. Overexpression of HISLA inhibits proliferation, migration, and invasion of HCC cells, while promoting apoptosis. Mechanisms involve potential regulation of metabolic pathways and interaction with other cancer-relevant signaling processes. HISLA may act as a tumor suppressor and serve as a prognostic molecular marker for patient selection and risk assessment in cancer[2]. HISLA belongs to the lncRNA family, which does not encode a protein but exerts functional effects via RNA-mediated regulation of gene expression. *Note*: While HISLA/LINC01146 is not a receptor, enzyme, or protein-coding gene, it is considered a therapeutic target due to its functional impact on cancer biology and patient prognosis. No direct drugs currently target HISLA; clinical investigation would focus on antisense or lncRNA modulation approaches.

Other names

HIF-1alpha-stabilizing long noncoding RNAHISLALINC01146long intergenic non-protein coding RNA 1146

Not directly targeted by drugs; hypothetical mechanisms would involve modulating its expression or function to suppress tumor growth or modify hypoxia responses